CPE, Mirae lead $100m Series B for China's JW Therapeutics
JW Therapeutics, a China cancer treatment specialist established by Bristol Myers Squibb-owned Juno Therapeutics and China’s WuXi AppTec, has received $100 million in Series B funding.
The round was led by CPE – formerly CITIC Private Equity – and Mirae Asset. Additional commitments came from Oriza Holdings and CR-CP Life Science Fund, a $300 million life sciences vehicle established...
More on Greater China
Latest News
VCs commit $50m to China's Medilink Therapeutics
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised $50 million in Series A funding across two tranches.
OrbiMed raises $800m for Asia life sciences fund
OrbiMed has closed its latest Asia life sciences fund, which primarily invests in China and India, with $800 million in commitments.
China cloud IoT provider Tuya files for US IPO
Tuya, a Chinese software platform for internet-of-things (IoT) systems that mainly offers platform-as-a-service (PaaS) products is pursuing a US IPO.